Clinical trials: Demyelinating Disorder
Multiple Sclerosis
Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod vs placebo in subjects with active RMS who are treated with DMF (Tecfidera®).
- Trial name
- POINT (NCT02907177)
- Testing
- Ponesimod
- Where
- 119 sites in United States, Australia and 18 more
- Volunteers
- 136 people
- Sponsor
- Actelion
Multiple Sclerosis
Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses
This is a proof of concept, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of Isoxsuprine in MS subjects experiencing a typical relapse.
- Trial name
- NCT03752307
- Testing
- Isoxsuprine Hydrochloride, Corticosteroid
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of New Mexico
Hurler's Syndrome, Maroteaux-Lamy Syndrome
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
The primary objective of this clinical trial is to evaluate the ability to achieve and sustain donor engraftment in patients with lysosomal and peroxisomal inborn errors of metabolism undergoing hematopoietic stem cell…
- Conditions
- Hurler's Syndrome, Maroteaux-Lamy Syndrome, Sly Syndrome, Alpha Mannosidosis
- Trial name
- NCT00668564
- Testing
- Stem Cell Transplantation, Cyclophosphamide, Campath-1H
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsing Remitting Multiple Sclerosis (RRMS)
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.
- Trial name
- TOFIINGO (NCT01499667)
- Testing
- Fingolimod
- Where
- 44 sites in Australia, Austria and 9 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Safety of Polyphenon E in Multiple Sclerosis Pilot Study
This study is an open label 6 month study. All subjects will be treated with Polyphenon E (400 mg EGCG twice a day) for six months. The main outcome of this pilot phase will be safety.
- Trial name
- NCT00836719
- Testing
- Polyphenon E
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Multiple Sclerosis
Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Multiple Sclerosis (MS) is an autoimmune disorder of the central nervous system. In MS, inflammation is known to attack areas of the brain, spinal cord, and optic nerves; resulting in disability.
- Trial name
- NCT03396822
- Testing
- Gadoteridol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Maryland, Baltimore
Multiple Sclerosis, Relapsing-Remitting
Natalizumab Re-Initiation of Dosing
The primary objectives of this study are to further evaluate the safety of natalizumab (Tysabri®) monotherapy by evaluating the risk of hypersensitivity and immunogenicity following re-exposure to natalizumab, and to confirm the…
- Trial name
- NCT00306592
- Testing
- BG00002 (natalizumab)
- Where
- 63 sites in United States, Canada
- Volunteers
- 404 people
- Sponsor
- Biogen
Multiple Sclerosis, Constipation
Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
The purpose of the study is to assess how safe and effective the drug Lubiprostone is in people with Multiple Sclerosis (MS)and moderate to severe MS-associated constipation.
- Trial name
- NCT01236534
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Rochester
Pseudobulbar Affect (PBA)
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Objectives of the study are to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 (capsules containing either 30 mg of dextromethorphan hydrobromide and 10 mg of quinidine sulfate [AVP-923-30] or 20…
- Trial name
- STAR (NCT00573443)
- Testing
- dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
- Where
- 62 sites in United States, Argentina and 1 more
- Volunteers
- 326 people
- Sponsor
- Avanir Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis
Phase 1 study to assess the safety and biological activity of ATX-MS-1467 in patients with relapsing forms of multiple sclerosis.
- Trial name
- NCT01097668
- Testing
- ATX-MS-1467
- Where
- 16 sites in Russia, United Kingdom
- Volunteers
- 43 people
- Sponsor
- Apitope Technology (Bristol) Ltd.
Multiple Sclerosis, Pain
Usability of the MeTime MS App
The Me Time MS Application was designed to enable self-administration of acupressure. Two forms of acupressure - either "relaxing" or "stimulating" protocols - are administered through the Me Time MS app.
- Conditions
- Multiple Sclerosis, Pain, Fatigue Symptom
- Trial name
- NCT07123272
- Testing
- Self-guided smartphone application for relaxing acupressure, Self-guided smartphone application for stimulating acupressure
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Michigan
Multiple Sclerosis
A Study to Test the Use of Duloxetine for Pain in MS
Many patients with Multiple Sclerosis experience pain that is caused by the effects of MS on the nervous system. The purpose of this study is to see if an investigational drug (Duloxetine) will reduce pain in subjects with MS.
- Trial name
- NCT00457730
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Multiple Sclerosis
Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis
This is a phase II, double-blinded, placebo-controlled, randomized, cross-over Study designed to determine the efficacy of multiple intrathecal administrations of autologous mesenchymal stem cell-derived neural progenitor cells…
- Trial name
- NCT03355365
- Testing
- Intrathecal MSC-NP injection, Intrathecal saline injection
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Tisch Multiple Sclerosis Research Center of New York
Multiple Sclerosis, Sclerosis
Aerobic Exercise for Remyelination in Multiple Sclerosis
This is a clinical trial to determine the feasibility of a stationary aerobic cycling intervention and explore if aerobic exercise independently promotes remyelination in people with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Sclerosis, Demyelinating Diseases, Autoimmune Diseases of the Nervous System
- Trial name
- NCT04539002
- Testing
- Aerobic exercise, Education Group Control
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Oregon Health and Science University
Secondary-progressive Multiple Sclerosis
Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis
To assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the…
- Trial name
- NCT04925557
- Testing
- Mayzent, Ocrevus
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- State University of New York at Buffalo
Multiple Sclerosis, Spasticity
A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.
- Trial name
- NCT01610687
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Jazz Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
The primary objective of the study is to assess the safety and tolerability of long-term treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants with relapsing remitting multiple sclerosis…
- Trial name
- EXTEND (NCT01797965)
- Testing
- BIIB019 (Daclizumab)
- Where
- 222 sites in United States, Argentina and 25 more
- Volunteers
- 1,501 people
- Sponsor
- Biogen
Multiple Sclerosis
Isokinetic Exercises in Patients With Multiple Sclerosis
The investigators evaluated the effects of isokinetic muscle strengthening exercises of the quadriceps and hamstring on muscle strength, joint position sense, pain, kinesiophobia and quality of life in patients with multiple…
- Trial name
- NCT03779724
- Testing
- exercises
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Aksaray University Training and Research Hospital
Relapsing Remitting Multiple Sclerosis (RRMS)
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
The primary objective of the study is to evaluate the evolution of walking capacity as measured by the timed 100-meter walk test (T100T), timed 25-foot walk test (T25FW), maximum walking distance (MWD), and Expanded Disability…
- Trial name
- TIMER (NCT00871780)
- Testing
- BG00002 (natalizumab)
- Where
- 15 sites in Belgium, Mexico and 4 more
- Volunteers
- 224 people
- Sponsor
- Biogen
Adrenoleukodystrophy
Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy
OBJECTIVES: I. Evaluate the clinical efficacy of combination glyceryl trierucate and glyceryl trioleate (Lorenzo's Oil) therapy in boys with X-linked adrenoleukodystrophy. II.
- Trial name
- NCT00004418
- Testing
- glyceryl trierucate/glyceryl trioleate
- Where
- 2 sites in United States
- Volunteers
- 126 people
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.